Shionogi - Database of Clinical Trials by Pharmaceutical Companies

All Categories Pharma Companies » Shionogi

Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: S-488410
Sponsors: Shiga University; Shiga University; Showa University; Fukushima Medical University; Tohoku University; Shionogi
Recruiting - verified May 2012
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus

Conditions: Atrophy; Vaginal Diseases
Intervention: Drug: Ospemifene
Sponsors: Shionogi Inc.; Shionogi; QuatRx Pharmaceuticals
Completed - verified April 2012
Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

Conditions: Atrophy; Vaginal Diseases
Interventions: Drug: Ospemifene (Dose 1); Drug: Ospemifene (Dose 2); Drug: Placebo
Sponsors: Shionogi Inc.; Shionogi; QuatRx Pharmaceuticals
Completed - verified April 2012
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg twice daily; Drug: dolutegravir placebo twice daily; Drug: Open-label dolutegravir 50mg twice daily
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified May 2012
A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: DTG; Drug: BCV; Drug: TVR
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Active, not recruiting - verified April 2012
A Study of Duloxetine in Fibromyalgia

Condition: Fibromyalgia
Interventions: Drug: Duloxetine 60 mg; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Shionogi
Recruiting - verified April 2012
Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Ortho-Cyclen; Drug: Dolutegravir; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified April 2012
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Recruiting - verified March 2012
A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects

Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir; Drug: Rlipivirine; Drug: GSK1265744
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi
Completed - verified March 2012
Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir; Drug: Methadone
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified March 2012
A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy

Condition: Opioid Induced Constipation
Interventions: Drug: Placebo once daily; Drug: 0.1 mg of S-297995 once daily; Drug: 0.2 mg of S-297995 once daily; Drug: 0.4 mg of S-297995 once daily
Sponsors: Shionogi Inc.; Shionogi
Recruiting - verified October 2011
Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder

Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: KAPVAY™ (clonidine hydrochloride); Drug: Placebo
Sponsors: Shionogi Inc.; Shionogi
Active, not recruiting - verified March 2012
Drug Interaction Study Between Dolutegravir and Prednisone

Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir; Drug: Prednisone
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified October 2011
Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Condition: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: Drug: Dolutegravir 50 mg tablet; Drug: Dolutegravir 50 mg oral granules
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified September 2011
Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Conditions: Healthy Subjects; Infection, Human Immunodeficiency Virus
Interventions: Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg; Drug: Dolutegravir 50 mg; Drug: abacavir 600 mg/lamivudine 300 mg
Sponsors: ViiV Healthcare; ViiV Healthcare; Shionogi; GlaxoSmithKline
Completed - verified August 2011